Dyadic International (NASDAQ:DYAI) Major Shareholder Sells 41,143 Shares of Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 41,143 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $1.84, for a total transaction of $75,703.12. Following the completion of the transaction, the insider owned 3,455,764 shares in the company, valued at $6,358,605.76. This represents a 1.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Dyadic International Stock Performance

Shares of NASDAQ:DYAI opened at $0.94 on Monday. The firm’s 50 day simple moving average is $0.77 and its 200-day simple moving average is $0.83. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. Dyadic International Inc. has a one year low of $0.65 and a one year high of $1.35. The firm has a market cap of $34.27 million, a PE ratio of -4.09 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The firm had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. As a group, equities analysts predict that Dyadic International Inc. will post 0.13 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $3.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marathon Capital Management purchased a new position in Dyadic International during the 3rd quarter valued at about $41,000. Bank of America Corp DE lifted its position in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International in the 3rd quarter worth approximately $190,000. Geode Capital Management LLC boosted its stake in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares in the last quarter. Finally, Apis Capital Advisors LLC bought a new position in shares of Dyadic International during the third quarter valued at approximately $1,817,000. 27.95% of the stock is currently owned by institutional investors.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.